Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Allergic rhinitis

Patients with sniffles: increasing prevalence and treatment costs

    • News
    • Pneumology
    • RX
  • 3 minute read

The symptoms of allergic rhinitis may occur seasonally or persist over a long period of time. The disease is a growing global problem. In addition, the cost of therapy is enormous and often underestimated.

Allergic rhinitis (AR) is a disease of the nasal mucosa. It is based on an IgE-mediated inflammatory reaction triggered by certain, usually harmless substances. In addition to the characteristic signs, an allergy test can confirm the suspicion. A prospective study in Germany, France, Italy, Spain, and the United Kingdom examined the burden of an AR. Seasonal, perennial AR, and co-occurrence of both types were distinguished. The data of 1482 patients were collected and matched with the records of 415 physicians. A large proportion of sufferers had moderate to severe symptoms (67.2%; n=996), 42.5% (n=630) had a persistent form, and 31.5% (n=467) had comorbidities such as asthma [1].

Growing problem

Compared to physicians, patients were significantly more likely to rate their disease as more severe in all three types queried (p<0.001). Especially for patients, the high burden of AR is a very serious issue: uncontrolled symptoms can negatively affect sleep, general well-being, and quality of life [1]. Further, this can be manifested by a drop in performance at school or work, anxiety and depression, as well as fatigue and mood swings [2].

The ARIA (Allergic Rhinitis and its Impact on Asthma) expert panel of the WHO sees an increasing prevalence of AR: more than 40-50% of allergy tests in Europe, the USA and Australia-New Zealand by skin or serum tests are positive. Of these, the majority of patients were diagnosed with AR and/or asthma. Conservative estimates suggest that approximately 500 million people worldwide suffer from AR. The trend is increasing, especially in regions where only low or moderate incidence of AR has been observed [2].

The 3-pillar therapy

Allergen avoidance is paramount in the treatment of AR. The allergen-specific immunotherapy is the second basic measure, with which a causal elimination of the problem is possible. In addition to subcutaneous administration, sublingual forms of the preparation are now also available, which are unlikely to cause anaphylactic shock.

Furthermore, symptomatic therapy with drugs plays a major role. H1 receptor antagonists of the 1st generation are now only used with restraint. Their biggest drawback: they can cause fatigue and anticholinergic effects. Therefore, H1 receptor antagonists of the 2nd generation preferred. Maximum plasma levels are reached after about an hour when taken orally, and nasal sprays or eye drops relieve symptoms in as little as half that time. In contrast, the full onset of action of the mast cell-stabilizing cromoglicic acid occurs after two weeks at the earliest, and often only moderate success is achieved.

Intranasal preparations

The situation is different with intranasal glucocorticoids: They are said to be the most effective. Also worth mentioning are intranasal anticholinergics, which are particularly suitable for the treatment of rhinorrhea in perennial allergic and non-allergic rhinitis [2]. In addition, §there are a growing number of studies advocating intranasal antihistamines, and guidelines continue to recommend primarily intranasal preparations [3].

High cost, low compliance

The economic impact of AR is enormous. In 2005, it was estimated that the U.S. incurred approximately USD 3.4 billion in total direct medical costs. Of this, nearly half was spent on prescription drugs. In addition, there are hidden costs due to antibiotics, asthma, chronic sinusitis or emergency hospital admissions, as well as indirect costs such as missed work days. In addition, the total cost to treat AR is increasing: while approximately 6 billion was spent in 2000, by 2005 the figure was 11.2 billion in the United States.

Nevertheless, many patients do not remain loyal to their therapy. Possible reasons: The medication does not relieve the symptoms as expected, undesirable side effects occur, or handling is impractical. Therefore, good patient compliance should be aimed for with tailored therapy, e.g., with intranasal anticholinergics [3].

Monika Lenzer

Literature:

  1. Canonica GW, et al: A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 (85): 17-25.
  2. Bousquet J, et al: Allergic rhinitis and its impact on asthma (ARIA) 2008 Update. Allergy 2008; 63(86): 8-160.
  3. Meltzer EO, et al: The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011; 106: S12-S16.
Related Topics
  • Allergic rhinitis
  • Antibiotics
  • Anxiety
  • Asthma
  • Compliance
  • Costs
  • Depression
  • Power drop
  • Therapy
Previous Article
  • 9th Lucerne Trend Days Health

Swiss Healthcare – Quo vadis?

  • Congress Reports
  • Prevention and health care
  • RX
View Post
Next Article
  • Diabetic foot syndrome?

Questions alone are not enough

  • Dermatology and venereology
  • Education
  • Endocrinology and Diabetology
  • Hematology
  • Nephrology
  • RX
View Post
You May Also Like
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
View Post
  • 3 min
  • Public Health

Outpatient care in Switzerland: situation report

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.